Astrana Health (ASTH) Q3 2026 Earnings Call Transcript
Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.
How this was made

The 30-second read
Why it matters
Strong earnings and cash flow may trigger buying interest; however, Medicaid attrition and cost pressures remain risks.
Market read
First‑report earnings release with material financial metrics; likely to move the stock in after‑hours trading.
What to watch
Potential Medicaid attrition and exchange membership losses could pressure margins later.
Background
Astrana Health reported Q3 2026 results, detailing revenue, EBITDA, free cash flow, debt repayment, and strategic initiatives.
Ticker impact
Q3 2026 earnings call disclosed record $1.02B revenue and $77.2M adjusted EBITDA, new guidance and free cash flow figures.
likely upward pressure as investors price in strong earnings and cash flow generation
Revenue and EBITDA both topped guidance; free cash flow strong and debt reduction improves balance sheet.
Market effects
Highlights strength in the managed‑care and risk‑bearing health services sector.
Positive for U.S. health‑care stocks, especially those with similar capitation models.
Limited to health‑care investors; no broader macro effect.
Counterpoint
If guidance falls short of market expectations despite absolute growth, the stock could face a pullback.
Key entities
- companyAstrana Health
Provider of risk‑bearing health‑care services.



